Did you mean?

Neuland Laboratories Ltd pe ratio

Vineet Laboratories Ltd pe ratio

Gennex Laboratories Ltd pe ratio

Home

Insights

Neuland Laboratories Ltd P/E Ratio

Neuland Laboratories Ltd P/E Ratio

download
stocks purchased

₹ 2.4 Cr

Volume transacted

stocks purchased

3.9 K

stocks traded

Image

Neuland Laboratories Ltd

NSE: NEULANDLAB

PE

26.6

Last updated : 21 May 15:30 pm

Key Highlights

    The P/E Ratio of Neuland Laboratories Ltd is 26.6 as of 21 May 15:30 pm .a1#The P/E Ratio of Neuland Laboratories Ltd changed from 52.9 on March 2019 to 14.2 on March 2023 . This represents a CAGR of -23.13% over 5 years. a1#The Latest Trading Price of Neuland Laboratories Ltd is ₹ 6199 as of 21 May 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 27.2. The PE Ratio of Finance industry is 13.6. The PE Ratio of IT - Software industry is 27.9. The PE Ratio of Pharmaceuticals industry is 27.7. The PE Ratio of Retail industry is 94.8. The PE Ratio of Textiles industry is 21.1. In 2023a1#The Market Cap of Neuland Laboratories Ltd changed from ₹ 865.18 crore on March 2019 to ₹ 2308 crore on March 2023 . This represents a CAGR of 21.69% over 5 years. a1#The Revenue of Neuland Laboratories Ltd changed from ₹ 221.68 crore to ₹ 390.37 crore over 8 quarters. This represents a CAGR of 32.70% a1#The EBITDA of Neuland Laboratories Ltd changed from ₹ 29.12 crore to ₹ 112.27 crore over 8 quarters. This represents a CAGR of 96.35% a1#The Net Profit of Neuland Laboratories Ltd changed from ₹ 9.97 crore to ₹ 67.56 crore over 8 quarters. This represents a CAGR of 160.31% a1#The Dividend Payout of Neuland Laboratories Ltd changed from 16.25 % on March 2019 to 7.91 % on March 2023 . This represents a CAGR of -16.47% over 4 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '1952.9
Mar '2022.5
Mar '2133.4
Mar '2220.8
Mar '2314.2

Fundamental Metrics

Market Cap

7,954 Cr

EPS

233.9

P/E Ratio (TTM) *

26.6

P/B Ratio (TTM) *

6.2

Day’s High

6250.0

Day’s Low

6118.75

DTE *

0.1

ROE *

23.4

52 Week High

7794.0

52 Week Low

2603.2

ROCE *

30.1

* All values are consolidated

* All values are consolidated

Image

Neuland Laboratories Ltd

NSE: NEULANDLAB

PRICE

6199.8

-28.95(-0.46%)

stock direction

Last updated : 21 May 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Neuland Laboratories Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Neuland Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value

Market Value

7,991

Asset Value

774

9.3 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Key Valuation Metric

Earnings

300 Cr

26.6 X

PE Ratio

Market Cap

₹7991Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

300 Cr

26.6 X

PE Ratio

Market Cap

₹7991Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Neuland Laboratories Ltd PE Ratio Calculation

  • The Price-to-Earnings (PE) ratio, also known as the P/E Ratio, is a fundamental financial metric used to assess the valuation of a company's stock in relation to its earnings performance. For Neuland Laboratories Ltd, the PE Ratio is calculated as follows:

P/E Ratio

=

Market Capitalization

Net Income

  • Given the current market conditions, Neuland Laboratories Ltd's Share Price stands at 6199.8. The Earnings per Share (Diluted) for the trailing twelve months (TTM) ending in 2024-05-21T00:00:00 is 233.89. Substituting the values into the formula, PE Ratio becomes as follows: PE Ratio = 6199.8/ 233.89= 26.63.

P/E Ratio

=

Stock Price

Earning Per Share

  • This indicates that Neuland Laboratories Ltd's stock is trading at approximately 26.63 times its earnings per share for the trailing twelve months. Alternatively, the PE Ratio can also be computed using the company's overall financial performance: PE Ratio = Market Cap / Net Income. Where Market Cap represents the total market capitalization of the company, and Net Income signifies the total earnings after expenses and taxes.

Understanding Neuland Laboratories Ltd’s PE Ratio (BSE: NEULANDLAB)

    The Price-to-Earnings (PE) ratio, used to assess Neuland Laboratories Ltd's stock (BSE: NEULANDLAB), indicates how many years it would take for the company to earn back the stock price. If a company earns ₹2 per share annually and its stock trades at ₹30, the PE ratio is 15, signifying a 15-year payback period assuming steady earnings. Earnings fluctuate, affecting the payback period, Growing earnings shorten the recovery time while declining earnings extend it. Shareholders favor shorter payback periods, preferring lower PE stocks. Among stocks with the same PE ratio, faster-growing businesses are preferred. A company with losses makes the PE ratio meaningless. Peter Lynch introduced the PEG ratio to compare stocks with different growth rates, dividing the PE ratio by the growth rate. A company is considered fairly valued when its PE ratio matches its growth rate. The PE ratio, applicable across industries, measures stock valuation based on earnings power. It indicates how quickly an investment can be recouped. Unlike the PB ratio, which assesses valuation based on the balance sheet, the PE ratio focuses on earnings. Overall, the PE ratio provides insights into stock valuation, aligning with investors' preference for faster returns.

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '19865
Mar '20364
Mar '212679
Mar '221317
Mar '232309

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22222
Sep '22294
Dec '22270
Mar '22415
Jun '23365
Sep '23421
Dec '23395
Mar '23390

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '2229
Sep '2270
Dec '2255
Mar '22128
Jun '2399
Sep '23141
Dec '23123
Mar '23112

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '2210
Sep '2238
Dec '2231
Mar '2285
Jun '2362
Sep '2389
Dec '2381
Mar '2368

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '190
Mar '2016
Mar '218
Mar '2210
Mar '238

* All values are a in %

About Neuland Laboratories Ltd

About Neuland Laboratories Ltd

    Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by Davuluri Sucheth Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.'92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr. NLL's products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate. During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form. Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI. The Company commenced commercial production of Ramipril, a cardiovascular drug for export to certain markets in 2002. The Company commenced commercial production of Citalopram Hydrobromide, an anti depressant, Pirbuterol Acetate, a bronchodilator, Levofloxacin, an anti bacterial, Levetiracetam, an anti convulsant in 2003. A subsidiary company of Neuland Laboratories Ltd was incorporated on January 4, 2007 in the State of Delaware, USA with its principal office in Orange County, California. During the year 2008-2009, Neuland Laboratories K.K., Japan was incorporated as a subsidiary of Company. During 2012-13, Company undertook a major reorganisation of businesses aimed at de-leveraging on one hand and on other hand narrowing the focus on core activities: APIs, Intermediates and Contract Manufacturing. Consequently, the Company divested its R&D activities by selling its Land and Building and some identified intellectual properties to Neuland Pharma Research Private Limited and its Peptides Research activities along with identified intellectual properties to Neuland Health Sciences Private Limited. It entered into a Joint Business Arrangement with API Corporation, Japan, a part of Mitsubishi Chemical, for manufacturing and sale of APIs and Intermediates. During 2013-14, the Company enhanced its product bouquet by launching 5 more products. It also enhanced its development portfolio to 22 molecules/ APIs created for launch between 2013 and 2016. It opened new office in New Jersey, provide them with quick support and coordinate in various business activities. In November 2016, the Board of Directors of the Company approved the Scheme of Amalgamation of Neuland Health Sciences Private Limited (Holding/ Parent Company) and Neuland Pharma Research Private Limited (fellow Subsidiary of the Holding Company) with the Company, as April 1, 2016, the Appointed Date of Scheme. The Company acquired multi product manufacturing facility Unit 3, with a capacity of about 197 kiloliters located at Gaddapotharam Village, in Sanga Reddy District, in December, 2017.

Neuland Laboratories Ltd News Hub

News

Neuland Laboratories AGM scheduled

Neuland Laboratories announced that the 40th Annual General Meeting(AGM) of the company wi...

Read more

11 May 2024 12:16

News

Board of Neuland Laboratories recommends Final Dividend

Neuland Laboratories announced that the Board of Directors of the Company at its meeting h...

Read more

10 May 2024 17:23

News

Neuland Laboratories schedules board meeting

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 10 Ma...

Read more

24 Apr 2024 11:24

News

Neuland Laboratories Ltd leads gainers in 'A' group

Sona BLW Precision Forgings Ltd, Quess Corp Ltd, ISGEC Heavy Engineering Ltd and Vakrangee...

Read more

12 Apr 2024 12:00

News

Neuland Laboratories spurts as Hyderabad unit clears USFDA inspection

The USFDA had conducted the inspection from 18 March 2024 to 22 March 2024 at company's un...

Read more

22 Mar 2024 14:08

News

Neuland Laboratories schedules board meeting

Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 8 Feb...

Read more

27 Jan 2024 12:56

Product Composition by Percentage (Revenue)

FAQs for PE of Neuland Laboratories Ltd

What is Neuland Laboratories Ltd current share price?

The current market price of Neuland Laboratories Ltd as of May 21, 2024 is ₹6199.80.

Is Neuland Laboratories Ltd a good investment?

As per BlinkX Score Neuland Laboratories Ltd scores 49 in Revenue, 92 in Profitability. However it's advisable to conduct comprehensive research or seek advice from experts to evaluate whether it aligns with your investment objectives.

What are Neuland Laboratories Ltd's total net assets?

According to Neuland Laboratories Ltd's most recent financial filings, the company's net assets total ₹774.4 Cr.

Is Neuland Laboratories Ltd making a profit or loss?

Neuland Laboratories Ltd's net Profit as of May 21, 2024 is close to ₹300 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199